Correlates of SGLT-2-inhibitiors Use Among Patients with Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus: Insights from the Department of Veterans Affairs

Rifai MA, Mahtta D, Ramsey DJ, et al.


Am Heart J

First published: December 27, 2021  DOI: 10.1016/j.ahj.2021.12.006


This study using data from the Veterans Affairs (VA) administrative and clinical dataset examined determinants of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) use among patients with concomitant atherosclerotic cardiovascular disease (ASCVD) and diabetes mellitus. The aim of the present analysis was to identify barriers and facilitators associated with SGLT-2i in a real-world contemporary patient population in order to improve utilization of these guideline-directed agents.

Recent trends have shown an increasing burden of atherosclerotic cardiovascular disease (ASCVD) and cardiovascular mortality that are paralleled by a rising prevalence of obesity and type 2 diabetes mellitus. Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have protective cardiovascular effects as shown in recent trials. However, few studies have examined the determinants of SGLT-2i use in a contemporary cohort of patients with ASCVD and diabetes mellitus.

Full Article